The urokinase-streptokinase pulmonary embolism trial (phase II) results.
D001794:Blood Pressure; D002302:Cardiac Output; D004341:Drug Evaluation; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011652:Pulmonary Circulation; D011655:Pulmonary Embolism / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D011859:Radiography; D011877:Radionuclide Imaging; D013299:Streptodornase and Streptokinase / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use*; D014655:Vascular Resistance
D005343:Fibrinolytic Agents; D013299:Streptodornase and Streptokinase; D014568:Urokinase-Type Plasminogen Activator